Joint Formulary & PAD

Beclometasone with formoterol (Fostair NEXThaler 100/6) - Chronic Obstructive Pulmonary Disease (COPD)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Inhaler (dry powder)
Associated Icons :
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Beclometasone with formoterol (Fostair NEXThaler 100/6)
Indication :
Chronic Obstructive Pulmonary Disease (COPD)
Group Name :
ICS LABA
Keywords :
ICS/LABAs, ICS LABAs, Respiratory, inhaled corticosteroids
Brand Names Include :
Fostair NEXThaler
Important Information :

Fostair NEXThaler 100/6

Prescribe by BRAND

Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
4

Other Indications

Below are listed other indications that Beclometasone with formoterol (Fostair NEXThaler 100/6) is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Chronic Obstructive Pulmonary Disease (COPD).

Committee Recommendations (1)

The locally preferred ICS/LABA devices are as follows:

Low carbon:

  • Fostair Nexthaler (beclometasone / formoterol DPI)
  • Fobumix Easyhaler (budesonide / formoterol DPI)
  • Relvar Ellipta (Fluticasone / vilanterol DPI)
  • Symbicort Turbohaler (budesonide / formoterol DPI)

Alternative devices:

  • Fostair (beclometasone / formoterol MDI)
  • Symbicort (budesonide / formoterol MDI)

Devices should be prescribed by BRAND

A spacer device should be used with MDI devices.

See full COPD guidelines below